⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →

Gland Pharma Limited (GLAND) — Financial Results | 10 August 2026(2 announcements)

· NSE 🔴 High Importance Neutral
By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings
1 Financial Results 🔴 High Importance Neutral 📄 PDF
📢 Key Event
Gland Pharma Q1 FY27 revenue up 20% YoY to ₹18,003 crores
🔄 What Changed
EBITDA margin improved to 27% from 24% YoY; PAT up 47% YoY to ₹3,170 crores
💡 Investor Takeaway
Strong CDMO growth and new product launches drove revenue and profit expansion, but B2B weakness in India offsets some momentum.

Gland Pharma reported Q1 FY27 revenue of ₹18,003 crores, up 20% YoY, with PAT at ₹3,170 crores, up 47% YoY. EBITDA margin improved to 27% from 24% YoY, while Adj. EBITDA margin stood at 28%. The company highlighted strong CDMO growth, new US product launches, and pipeline progress, though B2B declined in India and other core markets. Forward guidance was not provided in the presentation.

2 Financial Results 🔴 High Importance ✨ Positive 📄 PDF
MetricValue
Revenue₹18,003 Cr
Net Profit (PAT)₹3,170 Cr
📢 Key Event
Gland Pharma reports Q1FY27 revenue of ₹18,003 million, up 20% YoY, with PAT up 47% to ₹3,170 million.
🔄 What Changed
Revenue grew 20% YoY to ₹18,003 million; PAT grew 47% YoY to ₹3,170 million; EBITDA margin expanded to 27% from 24%; PAT margin improved to 18% from 14%; CDMO revenue grew 20% YoY; B2B revenue grew 19% YoY.
🔮 What's Next
Revenue potential of USD 90-100 million from CDMO partnership; technology transfer completion within two years; revenues expected from calendar year 2029; ongoing pipeline additions and co-development partnerships anticipated to drive future growth.
💡 Investor Takeaway
Strong revenue and PAT growth driven by CDMO and B2B expansion, with margins improving and a robust pipeline supporting sustained long-term growth.

Gland Pharma reported Q1FY27 revenue of ₹18,003 million, up 20% YoY, with PAT rising 47% to ₹3,170 million. Gross profit reached ₹11,759 million (19% YoY), while EBITDA margin expanded to 27% from 24% a year earlier. PAT margin improved to 18% from 14%, and CDMO and B2B segments each contributed 50% of revenue, growing 20% and 19% YoY respectively. The company highlighted strong demand for injectables, new product launches, and a robust CDMO pipeline supporting long-term growth.

⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →
📊 Stock Analysis — GLAND ✨ Ask AI About This

About Gland Pharma Limited (GLAND)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹47,645.3 Cr P/E: 42.2 ROE: 10.9% ROCE: 15.2% Div Yield: 0.69%

View full GLAND stock details →

📡 Get AI alerts when GLAND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAND — Free

💡 Ask AI about this filing

Ask AI Free →

📊 More GLAND filings

See all GLAND filings →

🔥 Also filed on 10 August 2026

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAND files new disclosures

Track GLAND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLAND — Free

Free account · 2 AI queries/day

⚡ StockFin Pro Go Pro — bigger Radar, no daily limits Upgrade

© 2026 StockFin.ai — AI-powered Indian stock research

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd